

## Wessex Regional Genetics Laboratory Publications 2022

Blakes AJM, Wai HA, Davies I, Moledina HE, Ruiz A, Thomas T, **Bunyan D, Thomas NS**, Burren CP, Greenhalgh L, Lees M, Pichini A, Smithson SF, Taylor Tavares AL, O'Donovan P, Douglas AGL, Genomics England Research Consortium, Splicing and Disease Working Group, Whiffin N, Baralle D, Lord J. 2022. A systematic analysis of splicing variants identifies new diagnoses in the 100,000 Genomes Project. *Genome Med.* **14** (1): 79.

Bunyan DJ, Saran M, Hobbs JI, Anderson DJ, Duncan-Flavell PJ, Howarth RJ, Callaway JLA, **Macpherson JN**. 2022. Apparent homozygosity for a gr/gr AZFc deletion in a 47,XYY man with oligozoospermia and secondary infertility. *J. Reprod. Infertil.* **23** (4): 296-302 [PMID: 36452190].

Catherwood MA, Wren D, **Chiecchio L**, Cavalieri D, Donaldson D, Lawless S, ElHassadi E, Hayat A, Cahill MR, O'Shea D, Sargent J, Stewart P, Maurya M, Quinn J, Murphy P, Gonzalez de Castro D, Mills K, **Cross NCP**, Forconi F, Iyengar S, Schuh A, Thornton P. 2022. *TP53* mutations identified using NGS comprise the overwhelming majority of *TP53* disruptions in CLL: results from a multicentre study. *Front. Oncol.* **12**: 909615.

**Dawoud AAZ**, Gilbert RD, Tapper WJ, **Cross NCP**. 2022. Clonal myeloipoiesis promotes adverse outcomes in chronic kidney disease. *Leukemia* **36**: 507-515.

Forde C, Burkitt-Wright E, Turnpenny PD, Haan E, Ealing J, Mansour S, Holder M, Lahiri N, Dixit A, Procter A, Pacot L, Vidaud D, Capri Y, Gerard M, Dollfus H, Schaefer E, Quelin C, Sigaudy S, Busa T, Vera G, Damaj L, Messiaen L, Stevenson DA, Davies P, Palmer-Smith S, **Callaway A**, Wolkenstein P, Pasmant E, Upadhyaya M. 2022. Natural history of *NF1* c.2970\_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study. *Eur. J. Hum. Genet.* **30** (3): 291-297 [PMID: 34897289].

Garrett A, Loveday C, King L, Butler S, Robinson R, Horton C, Yussuf A, Choi S, Torr B, Durkie M, Burghel GJ, Drummond J, Berry I, Wallace A, **Callaway A**, Eccles D, Tischkowitz M, Tatton-Brown K, Snape K, McVeigh T, Izatt L, Woodward ER, Burnichon N, Gimenez-Roqueplo A-P, Mazarotto F, Whiffin N, Ware J, Hanson H, Pesaran T, LaDuca H, Buffet A, Maher ER, Turnbull C; on behalf of Cancer Variant Interpretation Group UK (CanVIG-UK). 2022. Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, *SDHB* and *SDHD*. *Genet. Med.* **24** (1): 41-50 [PMID: 34906457].

Grosvenor SE, Davies JH, **Lever M, Sillibourne J, Mackay DJG**, Temple IK. 2022. A patient with multilocus imprinting disturbance involving hypomethylation at 11p15 and 14q32, and phenotypic features of Beckwith-Wiedemann and Temple syndromes. *Am. J. Med. Genet.* **188A** (6): 1896-1903 [PMID: 35266280].

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng W-J, Choi JK, Colmenero I, Coupland SE, **Cross NCP**, De Jong D, Tarek Elghetany M, Takahashi E, Emile J-F, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li X-Q, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron

E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. 2022. The 5<sup>th</sup> edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia* **36** (7): 1703-1719 [PMID: 35732831].

Lafferty N, **Salmon M**, **Cross NCP**, Singer I, Cooney A, Jayaprakash R. 2022. Chronic eosinophilic leukaemia associated with *JAK2* exon 13 insertion/deletion mutations. *Acta Haematol.* **145** (2): 201-206 [PMID: 34515041].

Lin S, Sanchez-Bretaña A, Leslie JS, Williams KB, Lee H, **Thomas NS**, **Callaway J**, Deline J, Arjuna Ratnayaka J, Baralle D, Schmitt MA, Norman CS, Hammond S, Harlalka GV, Ennis S, Cross HE, Wenger O, Crosby AH, Baple EL, Self JE. 2022. Evidence that the Ser192Tyr/Arg402Gln *in cis* Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B). *Genomic Medicine* **7** (1): 2 [PMID: 35027574].

Loong L, Cubuk C, Choi S, Allen S, Torr B, Garrett A, Loveday C, Durkie M, **Callaway A**, Burghel GJ, Drummond J, Robinson R, Berry IR, Wallace A, Eccles DM, Tischkowitz M, Ellard S, Ware JS, Hanson H, Turnbull C; on behalf of CanVIG-UK. 2022. Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of *BRCA1* and *MSH2* missense variants. *Genet. Med.* **24** (3): 552-563. [PMID: 34906453]

Loong L, Garrett A, Allen S, Choi S, Durkie M, **Callaway A**, Drummond J, Burghel GJ, Robinson R, Torr B, Berry IR, Wallace AJ, Eccles DM, Ellard S, Baple E, Evans DG, Woodward ER, Kulkarni A, Lalloo F, Tischkowitz M, Lucassen A, Hanson H, Turnbull C; on behalf of the CanVIG-UK. 2022. Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). *Genet. Med.* **24** (9): 1867-1877.

Lübke J, Schwaab J, Naumann N, Horny H-P, Weiß C, Metzgeroth G, Kreil S, **Cross NCP**, Sotlar K, Fabarius A, Hofmann W-K, Valent P, Gotlib J, Jawhar M, Reiter A. 2022. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis. *J. Clin. Oncol.* **40** (16): 1783-1794.

**Mackay D**, Blik J, Kagami M, Tenorio-Castano J, Pereda A, Brioude F, Netchine I, Papingi D, de Franco E, **Lever M**, **Sillibourne J**, Lombardi P, Gaston V, Tauber M, Diene G, Bieth E, Fernandez L, Nevado J, Tümer Z, Riccio A, Maher ER, Beygo J, Tannorella P, Russo S, Perez de Nanclares G, Temple IK, Ogata T, Lapunzina P, Eggermann T. 2022. First step towards a consensus strategy for multi-locus diagnostic testing of imprinting disorders. *Clin. Epigenetics* **14**: 143 [PMID: 36345041].

Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Xicoy Cirici B, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöcker M, Elena C, **Cross NCP**, Kiladjian J-J, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR; and on behalf of the MDS/MPN International Working Group. 2022. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. *BMC Cancer* **22**: 1013.

**Salmon M, White HE**, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Stastna Markova M, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Machova Polakova K, **Cross NCP**. 2022. Impact of *BCR::ABL1* transcript type on RT-qPCR amplification performance and molecular response to therapy. *Leukemia* **36**: 1879-1886.

**White HE, Salmon M**, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela J-M, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, **Cross NCP**. 2022. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. *Leukemia* **36** (7): 1834-1842 [PMID: 35614319].